Inhaled corticosteroids use in childhood respiratory diseases: an italian survey on pediatricians' prescription habits.
Administration, Inhalation
Adrenal Cortex Hormones
/ administration & dosage
Adult
Attitude of Health Personnel
Child
Cross-Sectional Studies
Drug Prescriptions
/ statistics & numerical data
Female
Habits
Humans
Italy
Male
Middle Aged
Pediatricians
/ psychology
Respiratory Tract Diseases
/ drug therapy
Retrospective Studies
Surveys and Questionnaires
Allergic rhinitis
Asthma
Children
Inhaled corticosteroids
Laryngitis
Preschool wheezing
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
14
05
2020
accepted:
02
02
2021
entrez:
16
2
2021
pubmed:
17
2
2021
medline:
5
11
2021
Statut:
epublish
Résumé
A national consensus document on inhaled corticosteroids (ICS) use in childhood, produced by the main Italian pediatric scientific societies, has been recently released. The aim of this study was to gather information on the current pediatricians' ICS prescription habits in Italy for the management of the most common pediatric respiratory diseases, namely allergic rhinitis (AR), asthma, preschool wheezing and laryngitis. From the 1st October 2018 to the 31st January 2019 a link to an online questionnaire was sent monthly through a newsletter to the members of the Italian Society of Pediatrics. The questionnaire included 18 items on ICS use in the most common pediatric respiratory diseases. Data collection and reporting was based on STROBE Statement Checklist for cross-sectional studies. One thousand-two questionnaires were returned from primary care pediatricians (39.1%), hospital pediatricians (38.7%), private practicers (16.4%), university pediatricians (3.1%) and Pediatrics residents (2.7%). We found a good adherence to the international guidelines on AR, with prevalent use of oral antihistamine (60.6%) in the secretive phenotype and nasal ICS in the obstructive phenotype (64.8%). In asthma exacerbations ICS are not used in 53.4% of cases, but they are used at high dose in 27.9% and at low dose in 18.7% of cases. In intermittent asthma, ICS are not chosen as a daily controller therapy in 54.1% of cases, while they are chosen as a low dose daily therapy in 44.5% of cases (high dose in 1.4%). In children with persistent asthma, ICS are chosen as a daily low dose therapy in 67.4% of cases and as a daily high dose therapy in 31%. In the management of preschool wheezing, when a long-term treatment is needed, ICS are chosen both alone and in association with antileukotrienes in 71.4% of cases. Children affected by recurrent asthma exacerbations and wheezing are closely followed up, in particular by their primary care pediatricians. The preference for certain molecules in the treatment of different respiratory diseases also emerged. Pediatricians' ICS prescription habits in Italy should be improved, especially in the management of asthma. Future surveys on a more numerous sample will be useful to analyze differences in prescription habits on the basis of pediatricians' work settings and geographical distribution.
Sections du résumé
BACKGROUND
BACKGROUND
A national consensus document on inhaled corticosteroids (ICS) use in childhood, produced by the main Italian pediatric scientific societies, has been recently released. The aim of this study was to gather information on the current pediatricians' ICS prescription habits in Italy for the management of the most common pediatric respiratory diseases, namely allergic rhinitis (AR), asthma, preschool wheezing and laryngitis.
METHODS
METHODS
From the 1st October 2018 to the 31st January 2019 a link to an online questionnaire was sent monthly through a newsletter to the members of the Italian Society of Pediatrics. The questionnaire included 18 items on ICS use in the most common pediatric respiratory diseases. Data collection and reporting was based on STROBE Statement Checklist for cross-sectional studies.
RESULTS
RESULTS
One thousand-two questionnaires were returned from primary care pediatricians (39.1%), hospital pediatricians (38.7%), private practicers (16.4%), university pediatricians (3.1%) and Pediatrics residents (2.7%). We found a good adherence to the international guidelines on AR, with prevalent use of oral antihistamine (60.6%) in the secretive phenotype and nasal ICS in the obstructive phenotype (64.8%). In asthma exacerbations ICS are not used in 53.4% of cases, but they are used at high dose in 27.9% and at low dose in 18.7% of cases. In intermittent asthma, ICS are not chosen as a daily controller therapy in 54.1% of cases, while they are chosen as a low dose daily therapy in 44.5% of cases (high dose in 1.4%). In children with persistent asthma, ICS are chosen as a daily low dose therapy in 67.4% of cases and as a daily high dose therapy in 31%. In the management of preschool wheezing, when a long-term treatment is needed, ICS are chosen both alone and in association with antileukotrienes in 71.4% of cases. Children affected by recurrent asthma exacerbations and wheezing are closely followed up, in particular by their primary care pediatricians. The preference for certain molecules in the treatment of different respiratory diseases also emerged.
CONCLUSIONS
CONCLUSIONS
Pediatricians' ICS prescription habits in Italy should be improved, especially in the management of asthma. Future surveys on a more numerous sample will be useful to analyze differences in prescription habits on the basis of pediatricians' work settings and geographical distribution.
Identifiants
pubmed: 33588923
doi: 10.1186/s13052-021-00988-8
pii: 10.1186/s13052-021-00988-8
pmc: PMC7885514
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Références
Arch Intern Med. 1999 May 10;159(9):941-55
pubmed: 10326936
J Allergy Clin Immunol. 2012 Aug;130(2):287-96; quiz 297-8
pubmed: 22664162
Cochrane Database Syst Rev. 2012 Dec 12;12:CD002308
pubmed: 23235589
Pediatrics. 2016 Jun;137(6):
pubmed: 27230765
N Engl J Med. 2006 May 11;354(19):1985-97
pubmed: 16687711
Ann Med. 2014 Feb;46(1):24-30
pubmed: 24328420
Pediatr Pulmonol. 2018 Dec;53(12):1670-1677
pubmed: 30394700
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001955
pubmed: 21249651
Pediatrics. 2006 Aug;118(2):644-50
pubmed: 16882819
Lancet. 2013 Oct 19;382(9901):1360-72
pubmed: 24041942
Br J Gen Pract. 2000 Feb;50(451):135-41
pubmed: 10750214
Ital J Pediatr. 2018 Apr 6;44(1):46
pubmed: 29625590
Epidemiol Prev. 2005 Mar-Apr;29(2 Suppl):6-8
pubmed: 16128547
Respir Med. 2006 Aug;100(8):1307-17
pubmed: 16412623
J Allergy Clin Immunol. 2004 Dec;114(6):1282-7
pubmed: 15577824
J Allergy Clin Immunol. 2008 Mar;121(3):548-57; quiz 558-9
pubmed: 18328886
Pediatrics. 2009 Mar;123(3):e519-25
pubmed: 19254986
J Allergy Clin Immunol. 2003 Apr;111(4):661-75; quiz 676
pubmed: 12704342
Pediatr Pulmonol. 2014 Apr;49(4):326-34
pubmed: 23929666
Respir Med. 1994 May;88(5):373-81
pubmed: 8036306
N Engl J Med. 1994 Sep 15;331(11):700-5
pubmed: 8058076
N Engl J Med. 2006 May 11;354(19):1998-2005
pubmed: 16687712